Published in J Neurooncol on June 10, 2010
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther (2013) 0.97
Common Chromosomal Fragile Site Gene WWOX in Metabolic Disorders and Tumors. Int J Biol Sci (2014) 0.95
WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study. Tumour Biol (2011) 0.87
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas. Front Oncol (2013) 0.86
WWOX: a fragile tumor suppressor. Exp Biol Med (Maywood) (2014) 0.84
Gene expression of WWOX, FHIT and p73 in acute lymphoblastic leukemia. Oncol Lett (2013) 0.83
Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer. Oncol Lett (2014) 0.82
Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines. Tumour Biol (2014) 0.80
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster. PLoS One (2015) 0.78
WWOX modulates the gene expression profile in the T98G glioblastoma cell line rendering its phenotype less malignant. Oncol Rep (2014) 0.75
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res (2002) 28.38
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res (2005) 1.91
Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene (2005) 1.90
WWOX in biological control and tumorigenesis. J Cell Physiol (2007) 1.66
Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res (2002) 1.62
Loss of WWOX expression in gastric carcinoma. Clin Cancer Res (2004) 1.55
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
A role for the WWOX gene in prostate cancer. Cancer Res (2006) 1.45
The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res (2004) 1.45
Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett (2005) 1.42
WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res (2003) 1.42
CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer (2006) 1.41
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest (1995) 1.35
Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer (2003) 1.33
MethylScreen: DNA methylation density monitoring using quantitative PCR. Biotechniques (2007) 1.33
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res (2003) 1.32
Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene (2002) 1.31
BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry (1999) 1.29
Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res (1996) 1.28
Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res (2003) 1.27
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res (2009) 1.25
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res (2002) 1.23
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.20
Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19
WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol (2009) 1.16
WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol (2005) 1.15
Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol (1990) 1.09
Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol (1998) 1.06
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res (2007) 1.05
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol (2005) 0.99
Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol (2002) 0.98
Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol (2004) 0.93
Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chromosomes Cancer (2006) 0.92
DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol (1998) 0.92
Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol (2000) 0.89
WWOX, a new potential tumor suppressor gene. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2007) 0.85
Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol (2005) 0.82
Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol (2010) 1.89
Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol Ther (2007) 1.57
WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene (2004) 1.47
Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.44
[Cardioverter-defibrillator in the treatment of arrhythmia induced by trastuzumab used in the adjuvant setting in a patient with positive human epidermal growth factor receptor type-2 breast cancer]. Kardiol Pol (2012) 1.38
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer (2007) 1.31
CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res (2009) 1.15
Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology (2006) 1.14
Characterization of Tula virus from common voles (microtus arvalis) in Poland: evidence for geographic-specific phylogenetic clustering. Virus Genes (2004) 1.12
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci (2012) 1.08
KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol (2003) 1.08
Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol (2003) 1.02
Does vimentin help to delineate the so-called 'basal type breast cancer'? J Exp Clin Cancer Res (2009) 0.96
Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature. Acta Ophthalmol Scand (2006) 0.92
Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast cancer risk. Mol Biol Rep (2011) 0.89
High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet (2009) 0.89
Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. Clin Breast Cancer (2012) 0.89
Raman spectroscopy and imaging: applications in human breast cancer diagnosis. Analyst (2012) 0.88
Effects of the commercial extract of aronia on oxidative stress in blood platelets isolated from breast cancer patients after the surgery and various phases of the chemotherapy. Fitoterapia (2011) 0.87
WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study. Tumour Biol (2011) 0.87
Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay. Pathol Res Pract (2006) 0.86
Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis. Oncol Rep (2012) 0.86
Angioganglioglioma: a transitional form between angioglioma and gangioglioma? Ultrastruct Pathol (2003) 0.85
Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining. Jpn J Clin Oncol (2006) 0.84
Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article. Pol J Pathol (2008) 0.84
Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients. PLoS One (2013) 0.83
Raman imaging at biological interfaces: applications in breast cancer diagnosis. Mol Cancer (2013) 0.83
cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer (2009) 0.83
Breast cancer relapse prediction based on multi-gene RT-PCR algorithm. Med Sci Monit (2010) 0.83
TRAIL protein expression in breast cancer cells correlates with nuclear grade. Arch Med Sci (2010) 0.82
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer. Mol Biol Rep (2012) 0.81
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat (2014) 0.80
Limited importance of the dominant-negative effect of TP53 missense mutations. BMC Cancer (2011) 0.80
Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation. Biochem Pharmacol (2005) 0.80
Primary spinal cord melanoma - a case report. Folia Neuropathol (2010) 0.80
Comparison of FIGO 1989 and 2009 recommendations on staging of endometrial carcinoma: pathologic analysis and cervical status in 123 consecutive cases. Int J Gynecol Pathol (2011) 0.80
Changes in plasma thiol levels induced by different phases of treatment in breast cancer; the role of commercial extract from black chokeberry. Mol Cell Biochem (2012) 0.80
Phase transitions in oleic acid and in human breast tissue as studied by Raman spectroscopy and Raman imaging. J Med Chem (2011) 0.80
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. Cancer Epidemiol Biomarkers Prev (2009) 0.79
Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control. Lung Cancer (2010) 0.79
WWOX oxidoreductase--substrate and enzymatic characterization. Z Naturforsch C (2011) 0.79
Correlation between VEGFR-2 receptor kinase domain-containing receptor (KDR) mRNA and angiotensin II receptor type 1 (AT1-R) mRNA in endometrial cancer. Cytokine (2012) 0.79
Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. Br J Haematol (2012) 0.79
Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.79
Atypical lipomatous tumor of the cheek - a case report. Otolaryngol Pol (2012) 0.79
Prognostic relevance of cyclin E expression in operable breast cancer. Med Sci Monit (2009) 0.79
The changes of blood platelet activation in breast cancer patients before surgery, after surgery, and in various phases of the chemotherapy. Platelets (2012) 0.78
Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. Pol J Pathol (2005) 0.78
Modified bacterial cellulose tubes for regeneration of damaged peripheral nerves. Arch Med Sci (2013) 0.78
Analysis of cancer tissues by means of spectroscopic methods. Contemp Oncol (Pozn) (2012) 0.78
A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. Med Sci Monit (2006) 0.78
Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study. Pharmacol Res (2013) 0.78
Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma. Genes Chromosomes Cancer (2015) 0.78
Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res (2010) 0.78
TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. DNA Cell Biol (2014) 0.78
Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL. Pol J Pathol (2010) 0.77
Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes. BMC Immunol (2009) 0.77
Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials? J Clin Oncol (2011) 0.77
Rhabdomyosarcomatous (myoblastic?) phenotype of metastatic malignant melanoma. A case report. Pol J Pathol (2002) 0.77
Detection of P53 mutations in different cancer types is improved by cDNA sequencing. Oncol Lett (2010) 0.77
Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis. Dig Dis Sci (2012) 0.77
[PARP inhibitors--theoretical basis and clinical application]. Postepy Hig Med Dosw (Online) (2012) 0.77
A comparison of the effects of Angiotensin IV on androgen-dependent and androgen-independent prostate cancer cell lines. J Renin Angiotensin Aldosterone Syst (2012) 0.77
Malignant acanthosis nigricans associated with prostate cancer: a case report. BMC Urol (2014) 0.77
[Abdominal Burkitt lymphoma mimicking the ovarian cancer. Case report and review of the literature]. Ginekol Pol (2008) 0.76
Relationship of P-cadherin expression to basal phenotype of breast carcinoma. Pol J Pathol (2007) 0.76
[Mesenchymal stem cells]. Postepy Biochem (2013) 0.75
Do Langerhans cells play a role in vulvar epithelium resistance to squamous cell carcinoma? Arch Immunol Ther Exp (Warsz) (2007) 0.75
[Ameloblastoma of the maxillary sinus--a case report]. Otolaryngol Pol (2008) 0.75
Solitary fibrous tumour of the tongue of an adolescent--a case report with immunohistochemical studies. Pol J Pathol (2009) 0.75
[Castleman disease--a case report]. Otolaryngol Pol (2008) 0.75
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor. J Obstet Gynaecol Res (2008) 0.75
Chemotherapy modulates the biological activity of breast cancer patients plasma: the protective properties of black chokeberry extract. Food Chem Toxicol (2012) 0.75